Monitoring biological therapies in psoriatic arthritis

Journal of Rheumatology

Volumn 36, Issue SUPPL. 83, 2009, Pages 69-70

  Spadaro, Antonio ^a   Scrivo, Rossana ^a   Spinelli, Francesca Romana ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adverse events; Biologic therapies; Psoriatic arthritis

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; INCIDENCE; INFECTION; LIVER TOXICITY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RISK BENEFIT ANALYSIS; SKIN CANCER; SURVIVAL; ARTICLE; DRUG ANTAGONISM; REGISTER;

ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; HUMANS; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349915946     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090230     Document Type: Conference Paper

References (15)

1. Salvarani C, Olivieri I, Pipitone N, et al. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. Clin Exp Rheumatol 2006;24:70-78
2. Solomon DH, Lunt M, Schneeweiss S. The risk of infection associated with tumor necrosis factor alpha antagonists. Making sense of epidemiologic evidence. Arthritis Rheum 2008;58:919-928
3. Helliwell PS, Taylor WJ; CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheumatol 2008;35:472-476
4. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66 Suppl III:iii2Biii22.
5. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-369 (Pubitemid 351281272)
6. Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008;67:1650-1651
7. Desai B, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-790 (Pubitemid 44350122)
8. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138-144 (Pubitemid 351339884)
9. Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:334-339
10. Wolfe F, Michaud K. Biological treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 2007;56:2886-2895
11. Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008;58:82-87
12. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-2172 (Pubitemid 44749774)
13. Tam LS, Tomlinson B, Chu TTW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology 2008;47:718-723 (Pubitemid 351619219)
14. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra associated adverse events. Arthritis Rheum 2003;48:2769-2772 (Pubitemid 37280604)
15. Cush JJ. Biologic drug use: USA perspectives on indications and monitoring. Ann Rheum Dis 2005;64;18-23.